MedTrace Logo

Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

NCT02414568 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-02-21

No results posted yet for this study

Summary

This study evaluates bendamustine in patients aged over 60 years with classical Hodgkin Lymphoma treated by prednisone, vinblastine and doxorubicin. 90 patients will be enrolled in this study.

Conditions

  • Classical Hodgkin Lymphoma

Interventions

DRUG

Bendamustine

Bendamustine 120 mg/m2 (IV) Day 1

DRUG

Prednisone

Prednisone 40 mg/m² PO

DRUG

Vinblastine

Vinblastine 6 mg/m² IV

DRUG

Doxorubicin

Doxorubicin 40 mg/m² IV

Sponsors & Collaborators

  • The Lymphoma Academic Research Organisation

    lead OTHER

Principal Investigators

  • Hervé Ghesquières, MD · The Lymphoma Academic Research Organisation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
61 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-17
Primary Completion
2018-12-14
Completion
2020-11-10

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02414568 on ClinicalTrials.gov